Adlai Nortye

ANLPhase 3

Adlai Nortye is a Cayman Islands-incorporated, China and US-based biotech company dedicated to discovering and developing novel anti-cancer treatments. Its strategy centers on advancing buparlisib, a drug with a history in other cancers, into a new pivotal indication (HNSCC) while building a broader pipeline targeting the tumor microenvironment. The company went public on the NASDAQ in 2023, raising capital to fund its late-stage clinical development and expand its research efforts.

Market Cap

$392.8M

Employees

50-100

Focus

Biotech

ANL · Stock Price

USD 7.407.60 (-50.67%)

Historical price data

AI Company Overview

Technology Platform

A therapeutic development platform focused on in-licensing clinical-stage oncology assets for new indications and internally researching novel mechanisms to modulate the tumor microenvironment, including STING agonists and PI3K inhibitors.

Pipeline Snapshot

8 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Buparlisib & Paclitaxel	Head and Neck Cancer	Phase 3
E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6)	Neoadjuvant Therapy in Rectal Cancer	Phase 1
Pelareorep	Advanced or Metastatic Breast Cancer	Phase 1
AN0025	Esophageal Cancer	Phase 1
AN0025	Lung Cancer Stage III	Phase 1

Opportunities

The primary growth opportunity is the potential approval and commercialization of buparlisib for HNSCC, addressing a clear unmet medical need.

Success could also enable expansion into other PI3K-driven cancers.

Additionally, the earlier-stage pipeline, particularly the novel STING agonist (AN1025) and internal discovery candidate (AN4005), offers long-term potential for creating new drug candidates and partnership deals.

Risk Factors

The company faces binary risk from its pivotal Phase 3 trial for buparlisib; failure would be catastrophic.

As a pre-revenue firm, it will require substantial additional capital, risking shareholder dilution.

It also operates in the highly competitive and costly oncology field with no commercial experience.

Competitive Landscape

Adlai Nortye competes in crowded spaces: its lead PI3K inhibitor faces competition from other targeted therapies in HNSCC, and its immuno-oncology pipeline (PI3Kγ, STING) competes with numerous biotechs and large pharma developing similar TME modulators. Its differentiation hinges on demonstrating superior efficacy in specific, high-need patient populations (e.g., post-PD-1 failure).

Publications

Patents

Pipeline